Marinus Pharmaceutical has closed on a $29.4 million first round of venture capital. Branford, CT-based Marinus is focused on developing new drugs for the central nervous system. Domain Associates, Sofinnova Ventures and Canaan Partners led the round with participation by Foundation Medical Partners and private investors. The biotech said that most of the funds will go to in-licensing and developing new, clinical-stage therapies to treat neurological, psychiatric and pain disorders.
- read this press release for more information